MDACC Study No:2011-0319 ( NCT No: NCT01428635)
Title:Eltrombopag for the management of thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia (CML) and Myelofibrosis (MF)
Principal Investigator:Gautam Borthakur
Treatment Agent:Eltrombopag
Study Status:Open
Study Description:The goal of this clinical research study is learn if eltrombopag can help
control or prevent low platelet counts in patients receiving treatment for CML
or myelofibrosis.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II/Phase III
Treatment Agents:Eltrombopag
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:GlaxoSmithKline
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Gautam Borthakur
For Clinical Trial Enrollment:713-563-1586
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults